Open an account

GSK

GSK · LONDON

$50.75−$0.46 (−0.90%)TodayMarket closed ·
Prev close $51.21

About GSK

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).

Employees
66,841
Headquarters
Brentford, Middlesex
Listed
May 22, 1972
Sector
Health Care
Industry
Pharmaceuticals
Website
gsk.com

GSK key statistics

Market cap
76.69B
Price-earnings ratio
0.00
Dividend yield
3.56%
Average volume
5.79M
Volume
3.18M
Open price
$50.78
High today
$50.92
Low today
$50.29
52 Week high
$61.70
52 Week low
$42.85

GSK (GSK) at a glance

GSK (GSK) last traded at $50.75, with a market cap of 76.69B, a price-to-earnings ratio of 0.00 and a dividend yield of 3.56%.

Today the stock has traded between $50.29 and $50.92. The current price is 0.9% above the day's low and 0.3% below its high.

Volume so far is 3.18M shares, below the average of 5.79M shares a day.

Over the past year GSK has ranged from $42.85 to $61.70, and now sits 42% of the way up that range.

GSK met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.505 per share against an estimate of $0.4735.

The average analyst price target is $59.66, 17.6% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 3 analyst ratings say Buy
  • Buy33.3%
  • Hold33.3%
  • Sell33.3%
Price target · 25 analystsAvg $59.66
Low
$39.35
Now
$50.75
High
$84.63

GSK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 9.9% on average.

  1. Q3 FY24: reported $0.497 per share against an estimate of $0.4482
  2. Q4 FY24: reported $0.232 per share against an estimate of $0.1958
  3. Q1 FY25: reported $0.449 per share against an estimate of $0.4087
  4. Q2 FY25: reported $0.465 per share against an estimate of $0.4319
  5. Q3 FY25: reported $0.55 per share against an estimate of $0.4876
  6. Q4 FY25: reported $0.255 per share against an estimate of $0.2346
  7. Q1 FY26: reported $0.465 per share against an estimate of $0.4478
  8. Q2 FY26: reported $0.505 per share against an estimate of $0.4735

GSK news

  • Vandana Singh

    GSK Wins FDA Approval For Chronic Hepatitis B Drug

  • Press releaseBusiness Wire

    Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)

  • FDA Approves First-Of-Its-Kind Chronic Hepatitis B Treatment; Approves Hibsago (Bepirovirsen) For Chronic Hepatitis B In Adults Without Cirrhosis

  • Press releaseBusiness Wire

    Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

  • Vandana Singh

    FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated

  • FDA Approves Immunotherapy That May Allow Certain Patients With Rectal Cancer To Avoid Chemotherapy, Radiation And Surgery

  • Vandana Singh

    Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

  • Press releasePRNewswire

    Viola Davis partners with GSK to educate adults 50 and older about their shingles risk

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.